Form 4: Alise Reicin, Director at Sana Biotechnology, Acquires Stock Options

Director Alise Reicin acquired stock options for 54,278 shares of Sana Biotechnology, Inc. at an exercise price of $7.36 on June 6, 2024.

Summary

• Alise Reicin, a director at Sana Biotechnology, Inc., filed a Form 4 on June 7, 2024.
• The form reports the acquisition of stock options to purchase 54,278 shares of common stock.
• The transaction occurred on June 6, 2024, with an exercise price of $7.36 per share.
• The options vest on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana.
• Following the transaction, Reicin directly owns derivative securities for 54,278 shares.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates